HistoSonics provides the Edison histotripsy system, a non‑invasive focused‑ultrasound platform that mechanically liquefies liver tumor tissue through controlled cavitation. Integrated real‑time ultrasound imaging guides beam placement and verifies treatment margins, enabling same‑day outpatient procedures with >90 % technical success and low major‑complication rates. The FDA‑cleared system is compatible with standard interventional radiology suites and targets unresectable liver lesions.
Funding
$250M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TBFounders
Product
Problem
Patients with primary or metastatic liver tumors often require invasive surgery or thermal ablation, which can be unsuitable for unresectable lesions, carry significant morbidity, and limit access to timely treatment.
Solution
HistoSonics offers the Edison histotripsy system, a non‑invasive focused‑ultrasound platform that delivers high‑amplitude, microsecond‑duration pulses to generate a controlled cavitation bubble cloud within the target tissue. The resulting mechanical liquefaction destroys tumor cells at the sub‑cellular level without heat or ionizing radiation. Real‑time ultrasound imaging guides beam placement and confirms treatment zones, enabling outpatient procedures performed by trained physicians. Clinical studies demonstrate >90 % technical success, low major‑complication rates, and rapid patient discharge, providing an alternative for patients who are not candidates for surgery or conventional ablation.
Target Audience
The primary customers are interventional radiologists, hepatologists, and oncologic surgeons at academic medical centers and large health systems seeking a non‑invasive option for liver tumor management.
Features
- Focused‑ultrasound histotripsy engine that creates a precise cavitation bubble cloud for mechanical tissue fractionation
- Integrated high‑resolution ultrasound imaging for real‑time targeting, monitoring, and verification of treatment margins
- FDA‑cleared indication for non‑invasive destruction of liver tumors, including unresectable lesions
- Outpatient workflow with same‑day discharge; procedures typically completed within 60 minutes
- Clinical evidence from >250 cases showing >90 % technical success and ≤7 % major complication rate
- Physician training program and electronic Instructions for Use (eIFU) to ensure safe deployment and consistent outcomes
- Compatibility with existing interventional radiology suites and hospital information systems via standard DICOM and HL7 interfaces